Market Overview

Andrew Left: Exact Sciences Cologuard Test Is Not Worth The Cost

Share:
Andrew Left: Exact Sciences Cologuard Test Is Not Worth The Cost
Related EXAS
Watch These 7 Huge Put Purchases In Tuesday Trade
Risk-Reward Still Suggests Exact Sciences Is A Buy, But Be Cautious
Related UNH
Cramer Finds A Way To Explain Stock Diversification With Fantasy Football
Dow 30 Earnings Score Card From The Past Week: IBM, Visa, Goldman And More
US Market Indexes Lower on Friday (GuruFocus)

According to Andrew Left, EXACT Sciences Corporation (NASDAQ: EXAS)'s Cologuard may be a good test, but it's not worth the full $500-$600 cost. 

Left was responding to a report that UnitedHealth Group Inc (NYSE: UNH) had added the company's Cologuard, an alternative to a colonoscopy, to its Coverage Determination Guideline, which could lay to rest questions about the product's efficacy. 

United Health did not respond to a request for comment regarding the guideline change. 

Left told Benzinga the key thing to note in the story of Exact Sciences is what United Health would pay to insure the test. 

The news was first reported on BenzingaPro

screen_shot_2017-05-30_at_5.47.18_pm.png

Left is short Exact Sciences, and has a $20 price target. The stock traded at $34.97 in after hours trading at time of publication. 

Posted-In: Andrew Left Citron ResearchBiotech News Short Sellers Exclusives General Best of Benzinga

 

Related Articles (EXAS + UNH)

View Comments and Join the Discussion!